Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy
BRISBANE, Calif. & NEW YORK--(BUSINESS WIRE)--Apr 2, 2019--Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE) today announced inter…
